Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

Neurology

Volumn 85, Issue 14, 2015, Pages 1240-1249

  Palmqvist, Sebastian ^a,c   Zetterberg, Henrik ^d,e   Mattsson, Niklas ^d,f,g   Johansson, Per ^h   Minthon, Lennart ^a,c   Blennow, Kaj ^d   Olsson, Mattias ^b   Hansson, Oskar ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; FLUTEMETAMOL F 18; TAU PROTEIN; AMYLOID BETA PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ANTERIOR CINGULATE; ARTICLE; BRAIN REGION; CEREBROSPINAL FLUID; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOBAL NEOCORTICAL UPTAKE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NERVOUS SYSTEM PARAMETERS; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; BRAIN; COGNITIVE DEFECT; COMPARATIVE STUDY; DEMENTIA; DIAGNOSTIC IMAGING; METABOLISM; PATHOLOGY; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; BRAIN; COGNITIVE DYSFUNCTION; DEMENTIA; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RADIONUCLIDE IMAGING; TAU PROTEINS;

EID: 84943227798     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001991     Document Type: Article

References (40)

1. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-279
2. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292
3. Blennow K, Zetterberg H, Haass C, Finucane T. Semagacestat's fall: where next for AD therapies? Nat Med 2013; 19: 1214-1215
4. Eli Lilly and Company. Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo (EXPEDITION 3). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine. Cited January 20, 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT01900665. NLM Identifier: NCT01900665
5. Karran E, Hardy J. Antiamyloid therapy for Alzheimer's disease: are we on the right road? N Engl J Med 2014; 370: 377-378
6. Seppala TT, Nerg O, Koivisto AM, et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 2012; 78: 1568-1575
7. Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011; 68: 1398-1403
8. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-144
9. Buerger K, Ewers M, Pirttila T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006; 129: 3035-3041
10. Degerman Gunnarsson M, Lindau M, Wall A, et al. Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: an exploratory study. Dement Geriatr Cogn Disord 2010; 29: 204-212
11. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512-519
12. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009; 1: 371-380
13. Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A. High PiB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 2010; 7: 56-66
14. Grimmer T, Riemenschneider M, Forstl H, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009; 65: 927-934
15. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009; 73: 1193-1199
16. Koivunen J, Pirttila T, Kemppainen N, et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid betaamyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008; 26: 378-383
17. Landau SM, Lu M, Joshi AD, et al. Comparing PET imaging and CSF measurements of Ab. Ann Neurol 2013; 74: 826-836
18. Mattsson N, Insel P, Donohue M, et al. Independent information from cerebrospinal fluid b-Amyloid and florbetapir imaging in Alzheimer's disease. Brain 2015; 138: 772-783
19. Mattsson N, Insel P, Landau S, et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Ann Clin Transl Neurol 2014; 1: 534-543
20. Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-Amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 2014; 71: 1282-1289
21. Tolboom N, van der Flier WM, Yaqub M, et al. Relationship of cerebrospinal fluid markers to 11CPiB and 18F-FDDNP binding. J Nucl Med 2009; 50: 1464-1470
22. Weigand SD, Vemuri P, Wiste HJ, et al. Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid. Alzheimers Dement 2011; 7: 133-141
23. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-269
24. Haftenberger M, Schuit AJ, Tormo MJ, et al. Physical activity of subjects aged 50-64 years involved in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr 2002; 5: 1163-1176
25. Nelissen N, Van Laere K, Thurfjell L, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009; 50: 1251-1259
26. Lundqvist R, Lilja J, Thomas BA, et al. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J Nucl Med 2013; 54: 1472-1478
27. Rosen WG, Mohs RC, Davis KL A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-1364
28. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413
29. Robin X, Turck N, Hainard A, et al. pROC: an opensource package for R and S1 to analyze and compare ROC curves. BMC Bioinformatics 2011; 12: 77
30. Benaglia T, Chauveau D, Hunter DR, Young D. Mixtools: an R package for analyzing finite mixture models. J Stat Softw 2009; 32: 1-29
31. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-Amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 343-349
32. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234
33. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis 2010; 21: 1119-1128
34. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid {beta}-Amyloid 42 and tau proteins as biomarkers of Alzheimer-Type pathologic changes in the brain. Arch Neurol 2009; 66: 382-389
35. Thal DR, Attems J, Ewers M. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies. J Alzheimers Dis 2014; 42: S421-S429
36. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-Amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98-106
37. De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010; 67: 949-956
38. Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. J Alzheimers Dis 2013; 33: 117-131
39. Klunk WE, Koeppe RA, Price JC, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 2015; 11: 1-15.e1-4
40. Vanderstichele H, Bibl M, Engelborghs S, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2012; 8: 65-73